Cancer Cell

Article	Citations
Oxidative Stress in Cancer	1199
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications	582
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy	503
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker	482
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance	476
Acquired Resistance to Immune Checkpoint Inhibitors	431
Overcoming Endocrine Resistance in Breast Cancer	411
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities	408
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion	377
Engineering CAR-T Cells for Next-Generation Cancer Therapy	338
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth	323
Proteogenomic and metabolomic characterization of human glioblastoma	319
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes	297
Clinical Challenges of Immune Checkpoint Inhibitors	277
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer	270
Seroconversion rates following COVID-19 vaccination among patients with cancer	267
Challenges and Opportunities for Pancreatic Cancer Immunotherapy	267
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	267
Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer	266
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma	264
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	257
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade	256
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate	255
Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation	250
Targeting the MAPK Pathway in KRAS-Driven Tumors	249

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	246
Response and Resistance to BCR-ABL1-Targeted Therapies	244
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas	239
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma	228
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance	215
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies	214
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial	213
Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells	213
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution	206
Targeting cell-cycle machinery in cancer	202
Microbiome and cancer	201
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition	195
YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis	193
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors	187
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma	187
COVID-19 and Cancer: Current Challenges and Perspectives	186
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	186
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19	184
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma	183
Advancing Cancer Research and Medicine with Single-Cell Genomics	179
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer	177
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy	176
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial	176
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver	174
Immunometabolic Interplay in the Tumor Microenvironment	173
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	168
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma	167
Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states	160
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade	159
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	158
Biomolecular Condensates and Cancer	155
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	155
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	153
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer	153
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	152
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL	151
Mutant p53 suppresses innate immune signaling to promote tumorigenesis	151
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	149
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity	148
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer	148
The Glioma Stem Cell Model in the Era of Single-Cell Genomics	147
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer	147
Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer	142
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis	140
Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma	140
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence	138
Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma	138
Artificial intelligence for clinical oncology	136
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer	134
Integrated Omics of Metastatic Colorectal Cancer	133

Immunomodulation by targeted anticancer agents	132
Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells	132
Immune phenotypic linkage between colorectal cancer and liver metastasis	129
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial	129
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	128
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer	126
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer	126
Tumor organoids: Opportunities and challenges to guide precision medicine	124
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy	124
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma	120
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer	120
Artificial intelligence for multimodal data integration in oncology	120
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	120
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth	119
Activating a collaborative innate-adaptive immune response to control metastasis	119
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma	115
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer	114
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity	114
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer	114
Pan-cancer integrative histology-genomic analysis via multimodal deep learning	113
Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription	111
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	111
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways	107
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms	106
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress	106
Dietary Approaches to Cancer Therapy	105
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway	105
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia	105
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation	104
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	104
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence	103
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment	101
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance	99
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1	98
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer	97
Immunogenomic Landscape of Hematological Malignancies	97
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy	97
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer	96
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies	94
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage	94
Melanoma models for the next generation of therapies	93
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	92
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study	92
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation	91
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response	91
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer	90
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies	90
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis	89
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma	89
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	88
Targeting pan-essential genes in cancer: Challenges and opportunities	88
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas	87
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity	86
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients	86
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies	85
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	84
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia	84
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma	82
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	81
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	79
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer	78
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	78
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies	77
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy	77
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia	76
Evaluation of cell-free DNA approaches for multi-cancer early detection	75
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance	74
PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression	74
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma	74
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity	73
Metabolic programming and immune suppression in the tumor microenvironment	73
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor	73
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support	70
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	70
Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer	69
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer	69
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity	69
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies	69
From bench to bedside: Single-cell analysis for cancer immunotherapy	67
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation	66

Cytokine Storms in Cancer and COVID-19	66
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	66
Tumor heterogeneity	65
Epigenomic Reprogramming as a Driver of Malignant Glioma	65
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance	65
Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance	65
Cell Lineage-Based Stratification for Glioblastoma	65
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	64
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer	64
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies	63
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment	62
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis	62
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia	62
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective	61
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function	59
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	59
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma	58
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity	58
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	58
Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia	57
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity	56
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis	56
Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells	56
Innate immune cells in the tumor microenvironment	56
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells	55
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	55
Pan-cancer proteomic map of 949 human cell lines	55
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model	54
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer	54
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	54
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma	52
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients	52
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer	51
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study	50
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	49
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma	48
B cells and cancer	48
Tumor microbiome links cellular programs and immunity in pancreatic cancer	48
Interleukin-1 in tumor progression, therapy, and prevention	48
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	48
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy	47
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	47
The therapeutic window of antibody drug conjugates: A dogma in need of revision	47
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer	47
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma	47
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	46
Functional Genomics for Cancer Drug Target Discovery	46
COVID-19: Staging of a New Disease	45
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer	45
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors	45
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration	45
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy	45
Cancer Patient Care during COVID-19	45
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution	45
The proteogenomic subtypes of acute myeloid leukemia	44
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	44
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients	43
Spatial profiling technologies illuminate the tumor microenvironment	43
Activated fibroblasts in cancer: Perspectives and challenges	42
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer	42
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity	42
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy	41
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	41
The translational challenges of precision oncology	41
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity	41
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma	41
Normal Somatic Mutations in Cancer Transformation	41
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop	40
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy	40
Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer	40
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy	40
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future	40
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer	40
Neutrophil-activating therapy for the treatment of cancer	38
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines	38
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation	37
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer	37
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy	37
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	36
Cancer Patients and Risk of Mortality for COVID-19	36
High-performance multiplex drug-gated CAR circuits	36
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening	35
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients	35
The role of exhaustion in CAR T cell therapy	35
Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings	35
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence	35
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer	34
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma	34
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas	33
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy	33
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer	33
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer	33
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma	33
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers	32
Detection and localization of early- and late-stage cancers using platelet RNA	32